15402-71-8

Usage

Uses

Used in Pharmaceutical Industry:
(Quinolin-8-yl)methanamine is used as a key intermediate in the synthesis of quinazolinone derivatives, which are known for their anti-tumor properties. These derivatives have shown potential in targeting and inhibiting the growth of cancer cells, making them valuable in the development of novel anticancer drugs.
Used in the Preparation of Anti-Tumor Agents:
(Quinolin-8-yl)methanamine plays a crucial role in the development of quinazolinone-based anti-tumor agents. These agents are designed to interfere with the cellular processes that promote tumor growth and proliferation, offering a promising avenue for cancer treatment and therapy.

Upstream product

• 109558-04-5 N-[8]quinolylmethyl-phthalimide 
• 91-22-5 quinoline 
• 611-32-5 8-methylquinoline 
• 1373436-69-1 N-(phenylsulfonyl)-N-(quinolin-8-ylmethyl)benzenesulfonamide 
• 1609646-64-1 N-(quinolin-8-ylmethyl)-4-(trifluoromethyl)benzenesulfonamide 
• 95-53-4 o-toluidine 
• 38707-70-9 8-formylquinoline 

Downstream Products

• 936220-18-7 8-{[3-(2,3-dichlorophenyl)-4H-1,2,4-triazol-4-yl]methyl}quinoline 
• 16032-35-2 8-hydroxymethylquinoline 

Relevant academic research and scientific papers

HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN

Disclosed herein are hydroxamic acid compounds. Also disclosed is a method of using the hydroxamic acid compounds for treating a condition associated with histone deacetylase 6.

Rhodium(III)-catalyzed intermolecular amidation with azides via C(sp 3)-H functionalization

The amidation reactions of 8-methylquinolines with azides catalyzed by a cationic rhodium(III) complex proceed efficiently to give quinolin-8- ylmethanamine derivatives in good yields via C(sp3)-H bond activation under external oxidant-free conditions. A catalytically competent five-membered rhodacycle has been isolated and characterized, revealing a key intermediate in the catalytic cycle.

Palladium-catalyzed intermolecular C(sp3)-H amidation

Dual capacity: A new palladium-catalyzed intermolecular sequence consisting of the C-H activation and amidation of methyl groups relies on N-fluorobis(phenylsulfonyl)imide (NFSI) as both the oxidant and the nitrogen source. The reaction provides the corresponding arylamines as bissulfonimides along with HF as the only by-product. Both experimental and computational results suggest the involvement of a monomeric palladium(IV) intermediate. Copyright

Quinazoline derivatives possessing anti-tumor activity

The invention relates to quinazoline derivatives, or pharmaceutically-acceptable salts thereof, which possess anti-tumor activity; to processes for their manufacture; and to pharmaceutical compositions containing them. The invention provides a quinazoline of the formula: STR1 wherein R1 is hydrogen or amino, or alkyl or alkoxy each of up to 6 carbon atoms; or R1 is substituted alkyl or alkoxy each of up to 3 carbon atoms; R2 is hydrogen, alkyl, alkenyl, alkynyl, hydroxyalkyl, halogenoalkyl or cyanoalkyl each of up to 6 carbon atoms; Ar is phenylene or heterocyclene; L is a group of the formula --CO.NH--, --NH.CO--, --CO.NR3 --, --NR3. CO--, --CH=CH--, --CH2 O--, --OCH2, --CH2 S--, --SCH2 --, --CO.CH2 --, --CH2.CO-- or --CO.O--, wherein R3 is alkyl of up to 6 carbon atoms; and Y is aryl or heteroaryl or a hydrogenated derivative thereof: or Y is a group of the formula --A--Y1 in which A is alkylene, cycloalkylene, alkenylene or alkynylene each of up to 6 carbon atoms and Y1 is aryl or heteroaryl or a hydrogenated derivative thereof; or a pharmaceutically-acceptable salt thereof.